PURPOSE: To identify factors affecting the quality of life (QoL) of disease-free survivors of rectal cancer. PATIENTS AND METHODS: One hundred twenty-one patients in complete remission more than 2 years after diagnosis were asked to complete three QoL questionnaires: the European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30; its colorectal module, QLQ-CR38; and the Duke generic instrument. RESULTS: Patients reported less pain (P =.002) than did controls drawn from the general population. EORTC QLQ-C30 physical scores were also higher among rectal cancer survivors than in the general Norwegian or German population (P =.0005 and P =.002, respectively). Unexpectedly, stoma patients reported better social functioning than did nonstoma patients (P =.005), with less anxiety (P =.008) and higher self-esteem (P =.0002). In the present authors' experience, the QLQ-CR38 does not discriminate between these groups. Residual abdominal or pelvic pain and constipation had the most negative influence on QoL. CONCLUSION: QoL is high among rectal cancer survivors, including stoma patients. Simultaneous use of several QoL questionnaires appears to have value in follow-up and in monitoring the effects of therapy. The impact of residual pain and constipation on long-term QoL should be considered when establishing a treatment regimen.
PURPOSE: To identify factors affecting the quality of life (QoL) of disease-free survivors of rectal cancer. PATIENTS AND METHODS: One hundred twenty-one patients in complete remission more than 2 years after diagnosis were asked to complete three QoL questionnaires: the European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30; its colorectal module, QLQ-CR38; and the Duke generic instrument. RESULTS:Patients reported less pain (P =.002) than did controls drawn from the general population. EORTC QLQ-C30 physical scores were also higher among rectal cancer survivors than in the general Norwegian or German population (P =.0005 and P =.002, respectively). Unexpectedly, stoma patients reported better social functioning than did nonstoma patients (P =.005), with less anxiety (P =.008) and higher self-esteem (P =.0002). In the present authors' experience, the QLQ-CR38 does not discriminate between these groups. Residual abdominal or pelvic pain and constipation had the most negative influence on QoL. CONCLUSION: QoL is high among rectal cancer survivors, including stoma patients. Simultaneous use of several QoL questionnaires appears to have value in follow-up and in monitoring the effects of therapy. The impact of residual pain and constipation on long-term QoL should be considered when establishing a treatment regimen.
Authors: Juan Ignacio Arraras Urdaniz; Fernando Arias de la Vega; Ruth Vera García; Ana Manterola Burgaleta; Maite Martínez Aguillo; Elena Villafranca Iturre; Esteban Salgado Pascual Journal: Clin Transl Oncol Date: 2006-06 Impact factor: 3.405
Authors: Martijn J L Bours; Bernadette W A van der Linden; Renate M Winkels; Fränzel J van Duijnhoven; Floortje Mols; Eline H van Roekel; Ellen Kampman; Sandra Beijer; Matty P Weijenberg Journal: Oncologist Date: 2016-02-24
Authors: Myong Hoon Ihn; Sung-Min Lee; Il Tae Son; Jin Taek Park; Heung-Kwon Oh; Duck-Woo Kim; Sung-Bum Kang Journal: Support Care Cancer Date: 2015-04-01 Impact factor: 3.603
Authors: David A Haggstrom; Neeraj K Arora; Paul Helft; Marla L Clayman; Ingrid Oakley-Girvan Journal: J Gen Intern Med Date: 2009-11 Impact factor: 5.128
Authors: Salvatore Pucciarelli; Paola Del Bianco; Fabio Efficace; Paola Toppan; Samantha Serpentini; Maria Luisa Friso; Sara Lonardi; Gian Luca De Salvo; Donato Nitti Journal: Support Care Cancer Date: 2009-07-23 Impact factor: 3.603
Authors: James A Martenson; Michele Y Halyard; Jeff A Sloan; Gary M Proulx; Robert C Miller; Richard L Deming; Stephen J Dick; Harold A Johnson; T H Patricia Tai; Angela W Zhu; Joan Keit; Kathy J Stien; Pamela J Atherton Journal: J Clin Oncol Date: 2008-09-02 Impact factor: 44.544